CJC-1295 (without DAC) / Ipamorelin blend
Pre-mixed lyophilised combination of CJC-1295 without DAC and Ipamorelin (5 mg + 5 mg per vial).
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-CJCIPA-10 · ≥99% (see COA) · Lyophilised powder
Note: Component ratio taken from the supplier list ("CJC-1295 without DAC 5mg + IPA 5mg"). Confirm the per-component content from the batch COA.
CJC-1295 (without DAC) / Ipamorelin blend overview
Each vial contains CJC-1295 without DAC 5 mg and Ipamorelin 5 mg (10 mg total peptide), co-lyophilised, per the supplier specification. See the individual component pages for data. Supplied for in-vitro laboratory research only.
CJC-1295 (without DAC) / Ipamorelin blend research background
Evidence status: This combination has not been studied as a blend; findings summarised here relate to the individual components, much of it preclinical (cell or animal) or small-scale. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
CJC-1295 (without DAC)
'CJC-1295 without DAC' (sometimes called modified GRF(1–29)) is a tetra-substituted GHRH(1–29) analogue without the albumin-binding complex. Little peer-reviewed research is publicly available for this compound. The published CJC-1295 human studies concern the DAC (albumin-binding) version and cannot be assumed to apply [1][2].
Ipamorelin
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) growth-hormone secretagogue. It was described in 1998 by Raun and colleagues as the first selective GH secretagogue [3]. It acts at the receptor later identified as the receptor for ghrelin [4].
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- This research blend combines 2 separately characterised compounds. The combination itself has not been studied in peer-reviewed research; the summaries below relate to each component individually. See each component's own product page for its full research background.
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
Human clinical research status
- No studies of this combination were identified. Clinical-status notes for individual components are summarised below; they do not apply to the blend.
- CJC-1295 (without DAC): No clinical studies of this specific analogue were identified. It is not an approved medicine.
- Ipamorelin: A Phase 2 randomised placebo-controlled trial in postoperative ileus after bowel resection found no significant difference from placebo in the primary endpoint [5]. Ipamorelin is not an approved medicine.
Safety observations reported in studies
- No safety data exist for the combination. Interactions between components have not been studied.
Known limitations
- The combination has not been studied; whether the components interact chemically or biologically in solution is unknown.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- CJC-1295 (without DAC): No credible peer-reviewed hypotheses specific to this analogue were found.
- Ipamorelin: Earlier rodent work led researchers to propose ghrelin-receptor agonists for gastrointestinal motility disorders. The human Phase 2 data did not confirm this [6][5].
Open scientific questions
- Whether the components are chemically compatible and stable when combined has not been reported.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683 · doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PubMed 17018654 · doi:10.1210/jc.2006-1702
- Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822 · doi:10.1530/eje.0.1390552
- Kojima M, Hosoda H, Date Y et al.. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PubMed 10604470 · doi:10.1038/45230
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030 · doi:10.1007/s00384-014-2030-8
- Venkova K, Mann W, Nelson R et al.. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009. PubMed 19289567 · doi:10.1124/jpet.108.149211
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Ipamorelin
CJC-1295 (without DAC)
AOD9604
CJC-1295 (with DAC)
Browse similar compounds: Endocrine & receptor-signalling research peptides, Research peptide blends or the full catalogue.